On October 1, 2016, amendments to regulations made under the
Ontario Drug Benefit Act ("ODBA") and the
Drug Interchangeability and Dispensing Fee Act
("DIDFA") came into force that aim to increase
access to existing unlisted drug products and also accelerate the
introduction of bioequivalent products into the market by way of a
faster review process and less stringent requirements for generic
line extension products.
To provide guidance to manufacturers seeking to navigate the drug submission process after this date, the Ontario Public Drug Programs published an addendum to the Ontario Guidelines for Drug Submission and Evaluation on October 6, 2016, which can be found here.
Increased access to unlisted, non-formulary drugs
Section 12 of Ontario Regulation 201/96 made under the ODBA
("ODBA Regulation") was amended to authorize the
executive officer to transition unlisted, non-formulary drugs
available through Ontario's Exceptional Access Program to the
Ontario Drug Benefit Formulary without a full submission by the
drug manufacturer, as previously required by the ODBA
If the executive officer is satisfied that the drug is clinically effective and has a low risk for inappropriate utilization, then the executive officer may transfer the drug from the Exceptional Access Program to the Ontario Drug Benefit Formulary. The goals of the amendment to the ODBA Regulation are to increase access to drugs that are known to be both safe and effective, increase availability to drugs that require urgent access, and increase availability of drugs that may be less costly than newer listed alternatives.
Faster review for all bioequivalent generic drugs
Amendments to Ontario Regulation 935 made under the
DIDFA ("DIDFA Regulation") are aimed at
permitting an accelerated review process for all generic products
that have been issued a Declaration of Equivalence from Health
Previously, there were two review processes (streamlined and non-streamlined) for listing generic products that had received a Declaration of Equivalence from Health Canada. Approximately 95% of products could be reviewed under the streamlined review process and be listed on the formulary in approximately two months.
These products primarily consisted of certain aqueous solutions, solid oral dosage forms for systemic effect, dermatological products that contain one or more glucocorticoids as the only active ingredient(s), and drug products with a transdermal route of administration for systemic effect. However, the remaining 5% of products were subject to a non-streamlined review process, which took approximately four months before listing and required review by the ministry's expert advisory committee, the Committee to Evaluate Drugs.
Increased/alternative access to interchangeability
Additionally, the amendments to the DIDFA Regulation will permit
a manufacturer of certain drug products to provide in
vitro studies to satisfy the executive officer that the drug
is interchangeable with a product listed on the
formulary.3 This provision of the DIDFA Regulation will
apply to drug products that have a non-systemic effect where Health
Canada has not issued a Declaration of Equivalence, and where blood
concentrations of the product cannot be measured and clinical
studies with a pharmacodynamic endpoint are inappropriate or
difficult to conduct.
New types of evidence permissible to allow for generic line extension products
In addition, the amendments to the DIDFA Regulation will allow
"generic line extension products" (i.e. new strengths for
existing drugs) to be considered for listing where no comparable
reference product exists in the same strength.4
Prior to the amendments, a generic manufacturer seeking listing on the formulary was required to show bioequivalence to the brand reference product in the same strength already considered to be clinically effective. The amendments now relieve generic manufacturers of this requirement by permitting the executive officer to accept alternative forms of evidence to establish that the generic line extension product is clinically effective, such as bioequivalence data and formulation proportionality data.
The Consolidated OBDA Regulation
The Consolidated DIDFA Regulation
Addendum 1 to the Ontario Guidelines for Drug Submission and Evaluation
Communication from the Executive Officer dated September 26, 2016
1 O. Reg 201/96 at ss. 12(2.1).
2 O. Reg 935 at ss. 6(3.1). Subsections 6(5.1), 6(6), 6(7), 6(7.1) and 6(7.2) are revoked.
3 O. Reg 935 at s. 6(6).
4 O. Reg 935 at s. 6(7).
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.